Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation

Journal Article · · Bioorganic and Medicinal Chemistry Letters

Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity. These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.

Research Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
INDUSTRY
OSTI ID:
1404982
Journal Information:
Bioorganic and Medicinal Chemistry Letters, Journal Name: Bioorganic and Medicinal Chemistry Letters Journal Issue: 12 Vol. 27; ISSN 0960-894X
Publisher:
Elsevier
Country of Publication:
United States
Language:
ENGLISH

Similar Records

Discovery of 5-Amino- N -(1 H -pyrazol-4-yl)pyrazolo[1,5- a ]pyrimidine-3-carboxamide Inhibitors of IRAK4
Journal Article · Thu Jun 11 00:00:00 EDT 2015 · ACS Medicinal Chemistry Letters · OSTI ID:1404964

Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation
Journal Article · Thu May 07 00:00:00 EDT 2015 · ACS Medicinal Chemistry Letters · OSTI ID:1404972

Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
Journal Article · Mon May 13 00:00:00 EDT 2019 · Journal of Medicinal Chemistry · OSTI ID:1544868